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Background: At the present time, there is a lack of data about the involvement of flotillins and stomatin in the
development of non-small cell lung cancer (NSCLC) and soft tissue sarcomas (STS). Moreover, changes in expression
of members of different families of the microdomain-forming proteins (caveolins and SPFH-domain containing family)
are usually investigated independently of each other. In this study we performed a combined analysis of flotillins,
stomatin, and caveolin-1 expression in these pathologies and evaluated correlations between generated data and
clinicopathological characteristics of the specimens.
Methods: The protein and mRNA expression was analyzed by Western blotting and real-time PCR, respectively, in
tissue specimens of patients undergoing surgery for non-small cell lung cancer and soft tissue sarcomas. Association
between expression of studied proteins and patient clinicopathological characteristics or outcome was evaluated.
Results: Stomatin protein expression was down-regulated in 80% of NSCLC samples and this decrease significantly
associated with presence of lymph node metastases. Flotillin-2 protein expression was up-regulated in the majority of
NSCLC samples whereas caveolin-1α expression was decreased. We revealed a strong correlation between STOM and
FLOT-1 mRNA expression in both pathologies, although the gene expression changes were diverse.
Conclusions: Our data demonstrate for the first time that expression of stomatin, a poorly studied microdomain-forming
protein, significantly changes in human tumors, thus pointing to its importance in the progression of NSCLC. We also
suggest the existence of some relationship between the expression of these proteins.
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Recently, the studies of the lipid rafts - membrane mi-
crodomains enriched with sphingolipids and cholesterol,
as well as a wide range of proteins, - have started to at-
tract increasing interest. A special type of lipid rafts is
microdomains stabilized by microdomain-forming pro-
teins (MFP), such as caveolins and SPFH (Stomatins,
Prohibitins, Flotillins, HflK/C) domain-containing pro-
teins. The caveolin family is one of the best studied and
the role of caveolin-1 is mainly determined by its ability* Correspondence: ksenia.arhipova@gmail.com
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reproduction in any medium, provided the orto form signalosomes, i.e. not only to support the integrity
of lipid rafts, but also, due to interaction with many resi-
dential signaling molecules, to coordinate and regulate
signal transduction in the cell [1]. As a result caveolin-1
can affect cell proliferation, programmed cell death,
migration and other processes important for tumor
transformation and progression. To date, the analysis
of caveolin-1 expression has been carried out in a wide
range of tumors and cell lines of various origins. It was
shown that, depending on the histogenesis of the tumor,
caveolin-1 may function as a tumor suppressor gene as
well as an oncogene.
The role of the SPFH superfamily in carcinogenesis
has been studied less extensively. Proteins of this super-
family, such as flotillins and stomatin, share a number ofral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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expressed in human tissues, primarily localized within
the plasma membrane, have similar topology, capability
for oligomerization and actively participate in the regu-
lation of signaling pathways, some of which intersect
with caveolin-dependent pathways. In the normal cell
physiology flotillins are involved in neuronal regeneration,
clathrin-independent endocytosis, glucose uptake, etc. [2-4].
Hazarika et al. demonstrated that metastasizing mela-
nomas are characterized by increased flotillin-2 expres-
sion. Moreover, the exogenous flotillin-2 expression in
melanoma cells leads to the acquisition of metastasizing
phenotype [5]. It has also been demonstrated that flotillin-1
plays an important role in cellular proliferation, and its
increased expression correlates with poor outcome in
patients with breast cancer and lung adenocarcinomas
[6-8]. Stomatin was first discovered as an essential compo-
nent of erythrocyte cellular membranes, and its absence
was related to the development of hereditary hemolytic
anemia [9]. Stomatin is also expressed widely in the hu-
man tissues; however, its functions have been studied only
scantily. It is known that stomatin modulates the activity
of acid-sensing ion channels [10] and influences glucose
uptake [11]. At the present time, there are no data on the
role of stomatin in carcinogenesis and no information
about stomatin expression in human tumors.
Lung cancer is the leading cause of cancer deaths
worldwide among both men and women. Identification
of the molecular markers determining the risk of occur-
rence and progression and approaches for therapeutic
treatment of lung cancer are the most significant import-
ant problems in molecular oncology. On the contrary, soft
tissue sarcomas (STS) have not been studied nearly as
extensive as lung cancer. However, this group of tumors
is quite diverse; there are over 100 histological variants
with individual clinical, prognostic and therapeutic fea-
tures, which make the study of this type of tumors
extremely important.
Here we present novel data on mRNA and protein
expression of stomatin, flotillin-1 and −2 in human adeno-
carcinoma and squamous cell lung carcinoma speci-
mens. We also examined mRNA expression of MFP and
caveolin-1α protein in the STS group. To our knowledge,
this is the first study to simultaneously investigate the pro-
tein expression of members of different MFP families in
human tumors of epithelial and mesenchymal origin. Our
results suggest some relationship between these proteins
and the existence of a strong correlation between STOM
and FLOT-1 mRNA expression, observed in both groups.
Results
Expression of microdomain-forming proteins in NSCLC
Here and later in this paper, by the term “down-regulation”
we mean “down-regulation in tumor samples comparedwith corresponding normal tissue samples”, by “up-
regulation” we mean “up-regulation in tumor samples
compared with normal tissue samples” and by “equal
expression” we mean “equal expression levels in tumor
and normal tissue samples”.
We investigated the mRNA expression of flotillin-1,
stomatin, and caveolin-1 using real-time PCR in 22
paired (tumor and corresponding normal tissue) samples
of adenocarcinomas and 26 paired samples of squamous
cell carcinomas (Additional file 1). The expression of all
investigated microdomain-forming proteins was down-
regulated in the majority of specimens. There were no
significant differences in the expression of these genes
in groups of samples divided according to clinicopatho-
logical characteristics (Table 1).
We performed a correlation analysis of caveolin-1, sto-
matin, and flotillin-1 mRNA expression in the whole group
of non-small cell lung cancer (NSCLC) specimens and in
its subgroups in accordance with the clinicopathological
characteristics of the specimens (Table 2). We used
Spearman's rank correlation coefficient to assess strength
of relationships between expression changes of studied
genes; the higher the absolute value of the correlation
coefficient (it changes from −1 to 1), the stronger the
linear relationship and the two variables tend to increase
or decrease together. Expression of stomatin and flotillin-1
demonstrated the strongest correlation which varied
insignificantly in different groups. The correlation between
the expression levels of caveolin-1 and flotillin-1 was found
in groups of patients with small tumors and early clinical
stages where it was stronger than in the whole group of
NSCLC specimens. The most attention drew the correl-
ation between caveolin-1 and stomatin expression because
it emerged in groups of patients with favorable charac-
teristics such as small tumor size (r = 0,666, p < 0,01,
Spearman’s rank correlation), absence of lymph nodal
metastases (r = 0,575, p < 0,01), high and moderate dif-
ferentiation degree (r = 0,463, p < 0,01) and early stage
of disease (r = 0,672, p < 0,01). It also should be noted
that the two main histological types of NSCLC (adeno-
carcinomas and squamous cell carcinomas) did not
differ in correlations between the expression of the
studied genes.
To investigate stomatin, flotillin-1, flotillin-2, and
caveolin-1α protein expression in NSCLC we performed
Western blot analysis (Figure 1). Expression of all MFP
was detected in all examined specimens, both in tumors
and normal ones. The results of the analysis and corre-
lations with clinical and pathological characteristics are
represented in Table 3. Stomatin protein expression
was decreased in 80% of tumor samples compared to
corresponding normal tissue samples and its down-
regulation was associated with positive lymph nodal
status (p < 0,05, χ2-test). Protein expression of flotillin-2
Table 1 Expressiona of microdomain-forming proteins mRNA in NSCLC
Stomatin (n = 48) Flotillin-1 (n = 47) Caveolin-1 (n = 48)
up equal down up equal down equal down
NSCLC 3 8 37 3 11 33 2 46
Adenocarcinomas 2 4 16 2 6 13 1 21
Squamous cell carcinomas 1 4 21 1 5 20 1 25
Tumor size
T1-T2 3 3 24 2 6 21 1 29
T3-T4 0 5 13 1 5 12 1 17
Lymph node status
N0 1 3 16 0 7 12 0 20
N+ 2 5 21 3 4 21 2 26
Clinical stage
I-II 2 2 22 1 6 18 1 25
III-IV 1 6 15 2 5 15 1 21
Degree of differentiation
High 1 0 1 0 0 1 0 2
Moderate 1 5 24 2 6 22 1 29
Low 1 3 12 1 5 10 1 15
aup – higher gene expression in tumors compared with normal tissue samples.
down – lower gene expression in tumors compared with normal tissue samples.
equal – no significant difference in gene expression in tumors versus normal tissue samples.
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their normal tissue, and a high level of flotillin-2 was
correlated with high and moderate differentiation de-
gree (p < 0,05, χ2-test). Analysis of the flotillin-1 protein
showed that its expression was decreased and increased
in approximately equal amounts of specimens, in 38%
and 40%, respectively. Moreover, these groups had simi-
lar clinicopathological characteristics and survival rates.
Caveolin-1α protein expression was decreased in 75%
of samples and in all others it was unchanged. We also
found a correlation between the small tumors and the
equal amounts of caveolin-1α in tumor and normal
tissues (p < 0,05, Fisher’s exact test). Another important
observation was that within the group of 12 paired
specimens with equal expression of caveolin-1α, 11 were
small size tumors (T1-T2) and, furthermore, 7 out of these
11 developed metastases in the lymph nodes.
To assess the prognostic significance of MFP expres-
sion changes we carried out a log-rank analysis of the
Kaplan-Meier survival curves for 35 patients. Although
we analyzed all the possible groups of samples (taking
into account expression changes of MFP and clinico-
pathological characteristics), statistically significant differ-
ences were detected only in groups of specimens divided
by stage (I-II vs. III-IV, p < 0,05, log-rank test) and by
tumor size (T1-2 vs. T3-4, p < 0,05), which is obvious. The
Cox’ univariant regression analysis was used to assess
the mortality hazard ratio which for patients withadvance stage of disease (III-IV) was HR = 3.854 (95.0%
CI 1.247-11.909, p < 0,05), and for patients with larger size
of tumors (Т3-4) was HR = 5.007 (95.0% CI 1.848-13.564,
p < 0,05).Expression of microdomain-forming proteins in soft
tissue sarcomas
We studied mRNA expression of caveolin-1, stomatin,
and flotillin-1 by real-time PCR in 37 paired samples,
and protein expression of caveolin-1α in 35 paired sam-
ples from the STS group. The evaluation of mRNA
expression was performed only in the group of malig-
nant tumors and the results are represented in Table 4.
As follows from the table, stomatin mRNA expression
increased in the majority of the mesenchymal tumor
specimens. However, such up-regulation is more typical
for malignant fibrous histiocytoma, one of the most aggres-
sive types of STS, where out of 7 studied specimens only in
one case stomatin mRNA levels were equal in normal and
tumor tissues. We also found differences in mRNA expres-
sion of caveolin-1 and flotillin-1 between liposarcomas and
other mesenchymal tumors (p < 0,05, χ2-test, Table 5).
Correlation analysis revealed strong relationships between
mRNA expression of stomatin and flotillin-1 (r = 0,666,
p < 0.01, Spearman’s rank correlation), caveolin-1 and
flotillin-1 (r = 0,492, p < 0.01), and a weaker one between
stomatin and caveolin-1 (r = 0.338, р = 0.047).
Table 2 Spearman’s rank correlations between caveolin-1, stomatin and flotillin-1 mRNA expression in groups of
tumors, divided according to clinicopathological characteristics
Group Spearman's rank correlation coefficients
Caveolin-1 and Stomatin Caveolin-1 and Flotillin-1 Stomatin and Flotillin-1
Histology
NSCLC 0,437 0,295a 0,849
Adenocarcinomas 0,469 NS 0,848
SCC 0,45 NS 0,816
Clinical stage
I-II 0,672 0,442b 0,863
III-IV NSc NS 0,869
Tumor stage
T1-T2 0,666 0,497 0,886
T3-T4 NS NS 0,777
Lymph node status
Positive NS NS 0,885
Negative 0,575 NS 0,901
Degree of differentiation
Moderate 0,463 NS 0,864
Poor NS NS 0,815
NSCLC – non-small cell lung cancer.
SCC – squamous cell carcinoma.
ap = 0.044.
bp = 0.027, for others – p < 0.01.
NS – statistically non-significant.
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in benign and malignant tumors. The expression of
caveolin-1α was decreased in samples from 23 of 29
(79,3%) patients with malignant tumors, in 3 (10,3%) cases
caveolin-1α expression was increased, and there were no
difference in expression levels of caveolin-1α between nor-
mal and tumor tissues in 3 (10,3%) other cases. Analysis
of specimens from 5 patients with benign tumors showed
no difference in protein expression of caveolin-1α between
normal and tumor tissues.Figure 1 Western blot analysis of expression of microdomain-forming
control. These representative samples illustrate the main trends of changes in
SCC – squamous cell carcinoma, AC - adenocarcinoma.Discussion
Expression changes of MFP correlate with
clinicopathological characteristics of specimens
In this work, we demonstrated for the first time that sto-
matin mRNA and protein expression changes in tumor
specimens of patients with NSCLC and soft tissue sarco-
mas. As there is a lack of data about stomatin participa-
tion in the main cancer-related signaling pathways, it
was especially interesting to found out its association
with positive lymph node metastasis status of patientsproteins in paired samples of NSCLC. Actin was used as a loading
transcription and protein expression. T – tumor tissue, N – normal tissue,
Table 3 Associations between expressiona of microdomain-forming proteins and clinicopathological characteristics of
NSCLC patients
Stomatin Flotillin-1 Flotillin-2 Caveolin-1







up 3 0 12 18
equal 1 1 4 10
down 0 2 14 17
p 0,242
Flotillin-2
up 3 2 15 11 7 5 24
equal 0 2 9 4 2 5 13
down 0 0 6 1 1 5 8
p 0,39 0,176
Caveolin-1
equal 1 1 6 5 3 1 4 6 1 12
down 3 3 26 13 6 16 19 7 7 36
p 0,925 0,155 0,107
Tumor size
T1-T2 4 1 20 12 7 10 12 11 5 11 20
T3-T4 0 3 13 6 3 7 12 2 3 1 16
p 0,094 0,816 0,117 0,036b
Lymph node status
N0 3 4 12 7 3 9 9 8 1 5 15
N+ 1 0 21 11 7 8 15 5 7 7 21
p 0,026c 0,476 0,078 1
Clinical stage
I-II 3 2 18 10 4 11 11 9 3 8 18
III-IV 1 2 15 8 6 6 13 4 5 4 18
p 0,714 0,459 0,277 0,505
Degree of differentiation
moderate 3 4 22 10 8 11 17 11 2 10 22
low 1 0 11 8 2 6 7 2 7 2 14
p 0,377 0,432 0,007c 0,289
aup – higher gene expression in tumors compared with normal tissue samples.
down – lower gene expression in tumors compared with normal tissue samples.
equal – no significant difference in gene expression in tumors versus normal tissue samples.
bFisher’s exact test.
cχ2 test.
Data in bold represents statistically significant values.
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expression is an unfavorable factor for lung cancer; how-
ever, the mechanisms of its action are unclear. Twopossible explanations for the down-regulation of stomatin
are that it is due to transcriptional regulation or change in
the methylation status of its promoter. These explanations
Table 4 Expressiona of microdomain-forming proteins mRNA in STS
Gene expression in tumors compared with normal tissue samples
Stomatin Flotillin-1 Caveolin-1
up equal down up equal down up equal down
Liposarcomas 5 5 5 3 3 8 0 3 12
Synovial sarcoma 3 1 2 4 2 0 3 0 3
Malignant fibrous histiocytoma 6 1 0 5 0 2 4 1 2
Malignant schwannoma 2 0 2 3 0 1 1 2 1
Other malignant tumors 2 0 1 1 1 1 2 0 1
aup – higher gene expression in tumors compared with normal tissue samples.
down – lower gene expression in tumors compared with normal tissue samples.
equal – no significant difference in gene expression in tumors versus normal tissue samples.
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in both mRNA and protein expression levels of stomatin
in the majority of tumor specimens.
Flotillin-2 protein up-regulation was detected in a half
of the studied samples, while down-regulation was ob-
served in 30%. Hazarika et al. showed that increased
expression of flotillin-2 was also typical for melanomas,
especially for the more aggressive metastasizing forms
[5]. We did not find association between changes in ex-
pression of flotillin-2 and lymph node status, neverthe-
less, we demonstrated correlation between its changes
and degree of differentiation. This fact may be explained
by findings of previous in vitro studies, which described
a direct relationship between degree of differentiation
and the expression rates of flotillin-2. Volonte et al.
showed that flotillin-2 up-regulates during differenti-
ation of skeletal myoblast cell line C2C12 [12]. A similar
result was obtained by Bickel et al. for 3 T3-L1 adipocyte
cell line [13]. By analyzing flotillin-1 protein expression,
we identified two equally sized groups (with increased and
down-regulated expression), which had similar clinical
and pathological parameters. Furthermore, our findings
contradict those reported by Zhang et al. [8], who de-
tected flotillin-1 up-regulation in the majority of studied
samples of lung adenocarcinomas and demonstrated its




up equal down up
Liposarcomas 5 5 5 3
Other malignant tumors 13 2 5 13
p <0,01b
aup – higher gene expression in tumors compared with normal tissue samples.
down – lower gene expression in tumors compared with normal tissue samples.
equal – no significant difference in gene expression in tumors versus normal tissue
bχ2 test.
NS – statistically non-significant.find any differences in flotillin-1 expression between
adenocarcinomas and squamous cell carcinomas, we
believe that this contradiction is due to differences in
sampling, methodology of investigation, or population
specifics. We also detected differences between mRNA
and protein expression of flotillin-1 in our samples,
which may be explained by post-translation regulation
or protein stability.
The results of caveolin-1α expression analysis agree
quite well with previously reported data for both groups of
tumors [14-18]. Immunohistochemical analysis of NSCLC
detected caveolin-1 expression in 15-30% of specimens
and the loss of the caveolin-1 expression correlated with
tumor progression, poor prognosis and drug resistance
[14-16]. In our study, we observed equal amounts of
caveolin-1 in tumor and normal tissues in 25% of samples,
while in the others it was down-regulated. Although we
did not find correlation of caveolin-1α expression with
prognosis, we made an interesting observation. Seven out
of 11 NSCLC samples with equal caveolin-1α protein
expression in tumor and normal tissues and tumor size
T1-T2 had lymph node metastases. This fact may be
explained by the hypothesis of Ravid et al. [19], according
to which the caveolin-1 expression is bi-phasic: i.e., it
decreases at the early stages of the tumor transformation
and increases later, at the stage of metastasis. According toming proteins between liposarcomas and other malignant
tumors compared with normal tissue samples
Flotillin-1 Caveolin-1
equal down up equal down
3 8 0 3 12
3 4 10 3 7
<0,05b NS
samples.
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majority of malignant STS are characterized by decreased
amount of caveolin-1 protein [17,18]. Of special interest,
in our opinion, are the results indicating that benign and
malignant mesenchymal tumors differ by caveolin-1 ex-
pression. While in malignant neoplasms the expression
of caveolin-1 is decreased, in benign tissue it is either
increased or ‘normal’ levels of the protein are registered;
this observation is also confirmed by the results of our
study. We observed decreased protein expression of
caveolin-1α in the majority of the malignant tumor
specimens. At the same time, no decrease in expres-
sion of caveolin-1α has been demonstrated in 5 studied
benign tumors.
Correlations between mRNA expression levels of
different MFP
Microdomain-forming proteins, due to the formation of
signal platforms within the plasma membrane, are able
to regulate a whole complex of intercellular pathways,
and those represent an attractive target for chemotherapy.
However, the relationships and mechanisms of possible
interactions between different MFPs are poorly studied,
although, they participate in common signal pathways
[20]. The fact that animals with caveolin gene knock
down are fertile and viable, whereas caveolin-1 is a key
regulator of a wide range of vitally important pathways
in the cell [21], may point to the existence of compensatory
mechanisms or microdomain-forming backup proteins.
This makes our study especially significant, as we were able
to estimate changes of four MFPs simultaneously.
Statistical analysis using Spearman’s rank correlation
test enabled us to reveal different correlations in NSCLC
which are more typical for groups of tumors with favor-
able clinicopathological characteristics. We suggest a hy-
pothesis according to which simultaneous changes in the
MFPs mRNA expression characterize a presence of a
certain in vivo regulatory relationships between proteins
at early stages of tumor development. Progression of the
disease (manifested in the increase of the size, decrease
of the differentiation degree, ability to form secondary
growth nodes) leads to an increasing misbalance of
intercellular signaling pathways and loss of correlations
between MFPs. On the other hand, the appearance of such
strong correlations may be a consequence of a transcription
regulation of the studied genes by common transcription
factors. It is known that the transcription of caveolin-1 and
flotillin-1 may be regulated by Sp1 and Ets-1 transcription
factors [22-24]. We found that the strongest correlation
in both studied groups of tumors was between mRNA
expression of stomatin and flotillin-1, although, the ex-
pression patterns were diverse. This may indicate the
existence of common mechanisms for their regulation
in cells of epithelial and mesenchymal origin.Conclusion
In this study, we demonstrated that the expression of
such MFPs as stomatin and flotillins changes in NSCLC
and STS. Some of these changes correlate with clinico-
pathological characteristics, such as tumor size, differ-
entiation degree, regional lymph node metastasis, and,
correspondingly, the stage of the disease. Therefore,
caveolin-1, stomatin and flotillins play an important
role in the progression of both types of tumors. The
discovery of correlations between mRNA expression of
MFPs contributes to the understanding of regulation of
these genes and may lead to a revision of the already
accumulated scientific data. Our findings, which have
demonstrated for the first time the role of stomatin in
carcinogenic processes, open new avenues for future
research on the functions of this protein, not only in
the hematopoietic cells, but, primarily, in other types of
cells, both in normal physiology and in pathology.
Methods
Ethics statement
The Institutional Review Board of N.N. Blokhin Russian
Cancer Research Center of the Russian Academy of
Medical Sciences approved the project and all patients,
who were involved in the study, gave written informed
consents that their samples could be used for investi-
gational purposes. Data were analyzed anonymously. All
potential participants who declined to participate or
otherwise did not participate were eligible for treatment
(if applicable) and were not disadvantaged in any other
way by not participating in the study.
Patients and specimens
Tumor tissue samples were obtained from 50 patients
with NSCLC and 40 patients with STS, who had under-
gone surgery at the Clinical Oncology Research Institute,
N.N. Blokhin RCRC RAMS between 2005 and 2007. The
corresponding adjacent normal tissue samples (normal
lung tissue for NSCLC and related mesenchymal tissue
for STS) were also obtained. The tumor clinicopathological
stages were determined according to the standard tumor
TNM classification systems of the International Union
Against Cancer (edition 6). The NSCLC group included 22
(44%) adenocarcinomas and 28 (56%) squamous cell car-
cinomas. There were 40 (80%) men and 10 (20%) women,
with a median age of 60.82 years (range 38 – 79 years).
Other specimens’ characteristics are presented in Table 6.
The mesenchymal tumor group consisted of 15 liposar-
comas (10 well-differentiated and 5 dedifferentiated),
7 malignant fibrous histiocytomas (six grade 3 and one
grade 2), 6 synovial sarcomas (four grade 3 and two
grade 2), 4 malignant schwannomas (two grade 3, one
grade 1 and one grade 2), one leiomyosarcoma, one
dermatofibrosarcoma, one spindle cell sarcoma and 5
Table 6 Tumor characteristics in 50 cases of NSCLC
Characteristics No. (%) of cases




Lymph node status pN0 21 (42)
pN1 13 (26)
pN2 16 (32)
Distant metastasis Absent 47 (94)
Present 3 (6)




Degree of differentiation High 2 (4)
Moderate 31 (62)
Low 17 (34)
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Sixteen tumors were located in soft tissues of the ex-
tremities, 21 in the retroperitoneal space, and 3 in the
soft tissue of the trunk. There were 16 (40%) men and
24 (60%) women, with a median age of 52.33 years
(range 17 – 81 years).
Total RNA extraction and reverse transcriptase PCR
Frozen primary tumor specimens were homogenized in
TRIzol reagent (Invitrogen) using a disrupter. Total RNA
was extracted according to the TRIzol protocol. The total
RNA of each sample was dissolved in RNase-free water
and stored at −80°C. Before cDNA synthesis all the RNA
samples were treated with DNase I (Fermentas) in order
to avoid genomic DNA contamination. The RNA (2 μg)
was reverse-transcribed in a 50 μl reaction using oligo-dT
primers and MMLV-reverse transcriptase (Promega).
Quantitative real-time PCR
Quantitative real-time PCR was performed on an iCycler
iQ5 (Bio-Rad) using the EvaGreen dye. PCR reactions
were carried out in a total volume of 25 μl containing
21.4 μl of PCR master mix, 3 μl of undiluted first-strand
cDNA and 3 pmol of forward and reverse primers each.
Sequences of the primers were as follows: caveolin-1,
5'-CCGCGACCCTAAACACCTC-3' (forward) and 5'-GC
CTTCCAAATGCCGTCAA-3' (reverse); stomatin, 5'-GG




5'-TTGCCATGGGTGGAATCATA-3' (forward) and5'-TCGGAGTCAACGGATTTGGT-3' (reverse). The
following run protocol was used: denaturation step (95°C,
10 min), amplification and quantification programs re-
peated 45 times (95°C for 30 s, 60°C for 30 s and 72°C
for 30 s). All the samples were amplified simultaneously
in triplicate in a one assay-run. The transcript levels
were normalized to those of GAPDH to account for
variability in the amount of cDNA in each sample, and
the relative expression levels were calculated using the
REST-2005 software (Corbett Research/Qiagen) [25]. Genes
with relative expression values greater than 1.5 or less
than 0.5 were considered to be up- or down-regulated,
respectively, in tumor tissues. Raw data are available in
Additional file 1.Western blot analysis
Frozen primary tumor specimens were transferred into
lysis buffer (10 mM Tris–HCl, pH 7.8, 100 mM NaCl,
10 mM EDTA, 1% Triton X-100, 10% glycerol, 0.1%
SDS, 0,5% deoxycholate, protease inhibitor cocktail (Roche)
and Halt phosphatase inhibitor cocktail (Thermo)) and
incubated for 16 hours at +4°C. The lysates were centri-
fuged. Equal amounts of protein (80 μg) were separated
by SDS-PAGE (10-12% separating gel) and transferred
onto polyvinylidene difluoride membranes (Millipore).
Immunodetection was performed using the caveolin-
1α-specific monoclonal antibody (C3437, Sigma), the
stomatin-specific monoclonal antibody (sc-134554, Santa
Cruz), the flotillin-1-specific and flotillin-2-specific mono-
clonal antibody (clone 18 and clone 29, respectively, BD
Transduction Laboratories), followed by chemiluminescent
detection. (Millipore). To ensure equal loading amounts
the blots were reprobed using a polyclonal antibody to
pan-actin (Cell Signaling). The protein levels were quanti-
fied by densitometry using ImageJ software (NIH, Bethesda,
MD, USA). These assessments were performed three times
and after that tumor-to-normal protein abundance ratios
were calculated. Protein expression was considered to be
increased or decreased in tumor specimens if the ratio was
less than 0.5 or more than 1.5, respectively. Raw data are
available in Additional file 1.Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics
19 software. The relationship between qualitative variables
was analyzed using the χ2 or Fisher's exact test. Correla-
tions between parameters were assessed according to the
Spearman nonparametric test. Survival curves were plotted
by the Kaplan-Meier method and compared using the
log-rank test. The survival data were evaluated using
univariate Cox regression analysis. The P-value of <0.05
was considered statistically significant.
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Additional file 1: Table S1. Clinicopathological characteristics and
microdomain-forming proteins expression in patients with non-small
cell lung cancer. Table S2. Clinicopathological characteristics and
microdomain-forming proteins expression in patients with soft
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